Retroperitoneal Lymph Node Dissection in Patients With High Risk Testicular Cancer

Stephen Williams, David W. McDermott, Winston Dock, Eamonn Bahnson, Alexander M. Berry, Graeme S. Steele, Jerome P. Richie

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: In patients with testicular cancer the percent of embryonal carcinoma and lymphovascular invasion in the primary tumor have been identified as risk factors for occult metastatic disease. We reviewed differences between primary and post-chemotherapy retroperitoneal lymph node dissection in patients at high risk. Materials and Methods: Patients who underwent retroperitoneal lymph node dissection at our institution from 1993 to 2006 were identified and the clinical charts were reviewed. A total of 247 patients with orchiectomy specimens containing greater than 30% embryonal carcinoma were identified and perioperative data were obtained. Results: Of 247 patients 133 (53%) had greater than 30% embryonal carcinoma, including 76 (57%) with combined lymphovascular invasion. Median followup was 3.49 years. Of the patients 76 (57%) and 57 (43%) underwent primary and post-chemotherapy retroperitoneal lymph node dissection, respectively, of whom most received bleomycin, etoposide and cisplatin. Positive lymph nodes were identified at surgery in 37 (49%) and 35 patients (61%) with primary and post-chemotherapy retroperitoneal lymph node dissection, respectively. Of patients with negative pathological findings at surgery surveillance computerized tomography postoperatively identified retroperitoneal masses in 2 (5%) and 3 (14%) of those who underwent a primary and a post-chemotherapy procedure, respectively. Operative data on the primary vs post-chemotherapy groups showed an estimated blood loss of 166 vs 371 cc, an operative time of 2.7 vs 3.3 hours and a hospital stay of 4.4 vs 4.7 days. There were no deaths in either group. Conclusions: Patients with greater than 30% embryonal carcinoma with or without lymphovascular invasion are at significant risk for metastatic disease and they can be successfully treated with primary retroperitoneal lymph node dissection. Recurrence rates based on computerized tomography evaluation were low and similar between the chemotherapy and nonchemotherapy treated groups.

Original languageEnglish (US)
Pages (from-to)2097-2102
Number of pages6
JournalJournal of Urology
Volume181
Issue number5
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Testicular Neoplasms
Lymph Node Excision
Embryonal Carcinoma
Drug Therapy
Tomography
Orchiectomy
Bleomycin
Etoposide
Operative Time
Cisplatin
Length of Stay
Lymph Nodes
Recurrence

Keywords

  • carcinoma
  • drug therapy
  • embryonal
  • lymph node excision
  • neoplasm invasiveness
  • testis

ASJC Scopus subject areas

  • Urology

Cite this

Williams, S., McDermott, D. W., Dock, W., Bahnson, E., Berry, A. M., Steele, G. S., & Richie, J. P. (2009). Retroperitoneal Lymph Node Dissection in Patients With High Risk Testicular Cancer. Journal of Urology, 181(5), 2097-2102. https://doi.org/10.1016/j.juro.2009.01.026

Retroperitoneal Lymph Node Dissection in Patients With High Risk Testicular Cancer. / Williams, Stephen; McDermott, David W.; Dock, Winston; Bahnson, Eamonn; Berry, Alexander M.; Steele, Graeme S.; Richie, Jerome P.

In: Journal of Urology, Vol. 181, No. 5, 05.2009, p. 2097-2102.

Research output: Contribution to journalArticle

Williams, S, McDermott, DW, Dock, W, Bahnson, E, Berry, AM, Steele, GS & Richie, JP 2009, 'Retroperitoneal Lymph Node Dissection in Patients With High Risk Testicular Cancer', Journal of Urology, vol. 181, no. 5, pp. 2097-2102. https://doi.org/10.1016/j.juro.2009.01.026
Williams, Stephen ; McDermott, David W. ; Dock, Winston ; Bahnson, Eamonn ; Berry, Alexander M. ; Steele, Graeme S. ; Richie, Jerome P. / Retroperitoneal Lymph Node Dissection in Patients With High Risk Testicular Cancer. In: Journal of Urology. 2009 ; Vol. 181, No. 5. pp. 2097-2102.
@article{b408cf1b296346eeb0f9713db174cc48,
title = "Retroperitoneal Lymph Node Dissection in Patients With High Risk Testicular Cancer",
abstract = "Purpose: In patients with testicular cancer the percent of embryonal carcinoma and lymphovascular invasion in the primary tumor have been identified as risk factors for occult metastatic disease. We reviewed differences between primary and post-chemotherapy retroperitoneal lymph node dissection in patients at high risk. Materials and Methods: Patients who underwent retroperitoneal lymph node dissection at our institution from 1993 to 2006 were identified and the clinical charts were reviewed. A total of 247 patients with orchiectomy specimens containing greater than 30{\%} embryonal carcinoma were identified and perioperative data were obtained. Results: Of 247 patients 133 (53{\%}) had greater than 30{\%} embryonal carcinoma, including 76 (57{\%}) with combined lymphovascular invasion. Median followup was 3.49 years. Of the patients 76 (57{\%}) and 57 (43{\%}) underwent primary and post-chemotherapy retroperitoneal lymph node dissection, respectively, of whom most received bleomycin, etoposide and cisplatin. Positive lymph nodes were identified at surgery in 37 (49{\%}) and 35 patients (61{\%}) with primary and post-chemotherapy retroperitoneal lymph node dissection, respectively. Of patients with negative pathological findings at surgery surveillance computerized tomography postoperatively identified retroperitoneal masses in 2 (5{\%}) and 3 (14{\%}) of those who underwent a primary and a post-chemotherapy procedure, respectively. Operative data on the primary vs post-chemotherapy groups showed an estimated blood loss of 166 vs 371 cc, an operative time of 2.7 vs 3.3 hours and a hospital stay of 4.4 vs 4.7 days. There were no deaths in either group. Conclusions: Patients with greater than 30{\%} embryonal carcinoma with or without lymphovascular invasion are at significant risk for metastatic disease and they can be successfully treated with primary retroperitoneal lymph node dissection. Recurrence rates based on computerized tomography evaluation were low and similar between the chemotherapy and nonchemotherapy treated groups.",
keywords = "carcinoma, drug therapy, embryonal, lymph node excision, neoplasm invasiveness, testis",
author = "Stephen Williams and McDermott, {David W.} and Winston Dock and Eamonn Bahnson and Berry, {Alexander M.} and Steele, {Graeme S.} and Richie, {Jerome P.}",
year = "2009",
month = "5",
doi = "10.1016/j.juro.2009.01.026",
language = "English (US)",
volume = "181",
pages = "2097--2102",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Retroperitoneal Lymph Node Dissection in Patients With High Risk Testicular Cancer

AU - Williams, Stephen

AU - McDermott, David W.

AU - Dock, Winston

AU - Bahnson, Eamonn

AU - Berry, Alexander M.

AU - Steele, Graeme S.

AU - Richie, Jerome P.

PY - 2009/5

Y1 - 2009/5

N2 - Purpose: In patients with testicular cancer the percent of embryonal carcinoma and lymphovascular invasion in the primary tumor have been identified as risk factors for occult metastatic disease. We reviewed differences between primary and post-chemotherapy retroperitoneal lymph node dissection in patients at high risk. Materials and Methods: Patients who underwent retroperitoneal lymph node dissection at our institution from 1993 to 2006 were identified and the clinical charts were reviewed. A total of 247 patients with orchiectomy specimens containing greater than 30% embryonal carcinoma were identified and perioperative data were obtained. Results: Of 247 patients 133 (53%) had greater than 30% embryonal carcinoma, including 76 (57%) with combined lymphovascular invasion. Median followup was 3.49 years. Of the patients 76 (57%) and 57 (43%) underwent primary and post-chemotherapy retroperitoneal lymph node dissection, respectively, of whom most received bleomycin, etoposide and cisplatin. Positive lymph nodes were identified at surgery in 37 (49%) and 35 patients (61%) with primary and post-chemotherapy retroperitoneal lymph node dissection, respectively. Of patients with negative pathological findings at surgery surveillance computerized tomography postoperatively identified retroperitoneal masses in 2 (5%) and 3 (14%) of those who underwent a primary and a post-chemotherapy procedure, respectively. Operative data on the primary vs post-chemotherapy groups showed an estimated blood loss of 166 vs 371 cc, an operative time of 2.7 vs 3.3 hours and a hospital stay of 4.4 vs 4.7 days. There were no deaths in either group. Conclusions: Patients with greater than 30% embryonal carcinoma with or without lymphovascular invasion are at significant risk for metastatic disease and they can be successfully treated with primary retroperitoneal lymph node dissection. Recurrence rates based on computerized tomography evaluation were low and similar between the chemotherapy and nonchemotherapy treated groups.

AB - Purpose: In patients with testicular cancer the percent of embryonal carcinoma and lymphovascular invasion in the primary tumor have been identified as risk factors for occult metastatic disease. We reviewed differences between primary and post-chemotherapy retroperitoneal lymph node dissection in patients at high risk. Materials and Methods: Patients who underwent retroperitoneal lymph node dissection at our institution from 1993 to 2006 were identified and the clinical charts were reviewed. A total of 247 patients with orchiectomy specimens containing greater than 30% embryonal carcinoma were identified and perioperative data were obtained. Results: Of 247 patients 133 (53%) had greater than 30% embryonal carcinoma, including 76 (57%) with combined lymphovascular invasion. Median followup was 3.49 years. Of the patients 76 (57%) and 57 (43%) underwent primary and post-chemotherapy retroperitoneal lymph node dissection, respectively, of whom most received bleomycin, etoposide and cisplatin. Positive lymph nodes were identified at surgery in 37 (49%) and 35 patients (61%) with primary and post-chemotherapy retroperitoneal lymph node dissection, respectively. Of patients with negative pathological findings at surgery surveillance computerized tomography postoperatively identified retroperitoneal masses in 2 (5%) and 3 (14%) of those who underwent a primary and a post-chemotherapy procedure, respectively. Operative data on the primary vs post-chemotherapy groups showed an estimated blood loss of 166 vs 371 cc, an operative time of 2.7 vs 3.3 hours and a hospital stay of 4.4 vs 4.7 days. There were no deaths in either group. Conclusions: Patients with greater than 30% embryonal carcinoma with or without lymphovascular invasion are at significant risk for metastatic disease and they can be successfully treated with primary retroperitoneal lymph node dissection. Recurrence rates based on computerized tomography evaluation were low and similar between the chemotherapy and nonchemotherapy treated groups.

KW - carcinoma

KW - drug therapy

KW - embryonal

KW - lymph node excision

KW - neoplasm invasiveness

KW - testis

UR - http://www.scopus.com/inward/record.url?scp=64049113908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64049113908&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2009.01.026

DO - 10.1016/j.juro.2009.01.026

M3 - Article

C2 - 19286227

AN - SCOPUS:64049113908

VL - 181

SP - 2097

EP - 2102

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -